Logo

Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar- ustekinumab in Russia and other CIS Countries

Share this
Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar- ustekinumab in Russia and other CIS Countries

Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar- ustekinumab in Russia and other CIS Countries

Shots:

  • Pharmapark to get exclusive rights to commercialize the therapy with a status of a local product & will be responsible for filing the report in Russia and other CIS countries
  • The agreement will utilize Pharmapark’s sales and marketing capabilities for the ustekinumab biosimilar program in Russia & other CIS countries. Bio-Thera will lead the development- and commercial supply of BAT2206 out of its manufacturing facilities in Guangzhou- China
  • Bio-Thera’s BAT2206 has completed a P-I study and is currently being evaluated in a P-III clinical study including patients from China- Russia- and other countries & plans to file for regulatory approval with the NMPA- EMA & FDA

Click here to­ read the full press release/ article | Ref: Businesswire | Image: Businesswire


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family